

REPORT

Operating expenses of the Board of Directors and the Supervisory Board

Respectfully submit to: The General Meeting of Shareholders

Pursuant to Article 25; Paragraph 4 of Article 33 of the Charter of Imexpharm Corporation;

Pursuant to the Audited financial statements for fiscal year 2021;

The Board of Directors would like to present operating expenses of the Board of Directors and the Supervisory Board 2021 and the usage of bonus due to exceeding business target as followings:

1. Remuneration of the Board of Directors and Supervisory Board

| | |
|---|-------------------|
| - Previous year unpaid expenses transferred: | VND 3,824,851,973 |
| - Distributed expense (2% Profit before expenses) | VND 4,874,668,777 |
| - Actual paid in 2021 | VND 5,326,822,222 |
| - Residual expenses transferred to 2022: | VND 3,372,698,528 |

2. Cash bonus to Board of Directors and Supervisory Board

| | |
|---|-----------------|
| - Previous year unpaid cash bonus transferred | VND 565,702,377 |
| - Cash bonus distributed from profit of 2021: | VND 0 |
| - Paid cash bonus in 2021 : | VND 565,400,000 |
| - Residual transferred to 2022: | VND 302,377 |

We kindly present to the General Meeting of Shareholders.

Yours faithfully,

Reciever:

- As stated above
- Archive

ON BEHALF OF THE BOARD OF DIRECTORS
CHAIRMAN

NGUYEN QUOC DINH